Post- marketing er der rapporteret om sjældne tilfælde af hepatosplenisk T- celle lymfom hos patienter i behandling med adalimumab (se punk 4. 4).
Rare post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with adalimumab (see section 4.4).